• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1998 年肝性脑病定义、命名和诊断工作组最终报告回顾。

Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.

机构信息

Servicio de Gastroenterología, Hospital Español de México. Policlínica Ángel Urraza Saracho. México, D.F.

出版信息

Ann Hepatol. 2011 Jun;10 Suppl 2:S36-9.

PMID:22228879
Abstract

Hepatic encephalopathy (HE) is a heterogeneous disease that develops as a result of serious liver disease, such as in fulminant hepatitis or cirrhosis, or a portosystemic shunt. It manifests as a spectrum of abnormalities involving cognition, attention, functional ability, personality and intellect. The neuropsychiatric impairment associated with HE can range from mild alteration of cognition and consciousness to coma, depending on the stage of the illness. In 1998, the World Gastroenterology Organization formed a working party to develop guidelines and recommendations for the diagnosis, grading and treatment of HE for research and practice. In this report, we discuss the various tests available for diagnosis and grading and the recommendations of the working party, which provide a framework for further studies on clinical trial methodology.

摘要

肝性脑病(HE)是一种异质性疾病,是严重肝脏疾病(如暴发性肝炎或肝硬化,或门体分流)的结果。它表现为一系列涉及认知、注意力、功能能力、人格和智力的异常。与 HE 相关的神经精神损害范围从认知和意识轻度改变到昏迷,取决于疾病的阶段。1998 年,世界胃肠病组织成立了一个工作组,为 HE 的诊断、分级和治疗制定研究和实践的指南和建议。在本报告中,我们讨论了可用于诊断和分级的各种检测方法以及工作组的建议,为临床试验方法学的进一步研究提供了框架。

相似文献

1
Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.1998 年肝性脑病定义、命名和诊断工作组最终报告回顾。
Ann Hepatol. 2011 Jun;10 Suppl 2:S36-9.
2
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.肝性脑病——定义、命名、诊断及量化:1998年于维也纳召开的第11届世界胃肠病学大会工作小组最终报告
Hepatology. 2002 Mar;35(3):716-21. doi: 10.1053/jhep.2002.31250.
3
Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.1998年肝性脑病定义、命名及诊断工作小组最终报告综述
Aliment Pharmacol Ther. 2007 Feb;25 Suppl 1:11-6. doi: 10.1111/j.1746-6342.2006.03216.x.
4
Review article: the modern management of hepatic encephalopathy.综述文章:肝性脑病的现代治疗管理。
Aliment Pharmacol Ther. 2010 Mar;31(5):537-47. doi: 10.1111/j.1365-2036.2009.04211.x. Epub 2009 Dec 7.
5
[Hepatic encephalopathy: recent developments].[肝性脑病:近期进展]
Rev Med Suisse. 2014 Sep 3;10(440):1612, 1614-6.
6
Optimal treatment of hepatic encephalopathy.肝性脑病的最佳治疗方法。
Minerva Gastroenterol Dietol. 2014 Mar;60(1):55-70.
7
RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.利福昔明对肝硬化患者轻微肝性脑病(MHE)及肠道微生物群的影响:一项随机对照试验的研究方案
Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.
8
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.演变的概念:轻微肝性脑病的负面影响和肝硬化患者预防的作用。
Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22.
9
Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.利福昔明与乳果糖治疗轻微肝性脑病的对比研究
Liver Int. 2016 Mar;36(3):378-85. doi: 10.1111/liv.12921. Epub 2015 Aug 17.
10
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.利福昔明联合乳果糖与单用乳果糖治疗肝性脑病的比较。
J Assoc Physicians India. 2017 Aug;65(8):42-46.

引用本文的文献

1
Successful splenic arteriovenous shunt embolization for hepatic encephalopathy associated with splenic arteriovenous shunt and intrahepatic portosystemic venous shunt.成功进行脾动静脉分流栓塞术治疗与脾动静脉分流及肝内门体静脉分流相关的肝性脑病。
Radiol Case Rep. 2025 Aug 13;20(11):5523-5526. doi: 10.1016/j.radcr.2025.07.036. eCollection 2025 Nov.
2
Extra-Synaptic GABA Receptor Potentiation and Neurosteroid-Induced Learning Deficits Are Inhibited by GR3027, a GABA Modulating Steroid Antagonist.外突触 GABA 受体增强和神经甾体诱导的学习缺陷被 GABA 调节甾体拮抗剂 GR3027 抑制。
Biomolecules. 2023 Oct 9;13(10):1496. doi: 10.3390/biom13101496.
3
Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis.
伊朗肝硬化患者轻微肝性脑病的检测
Middle East J Dig Dis. 2018 Oct;10(4):230-235. doi: 10.15171/mejdd.2018.115. Epub 2018 Sep 4.
4
The abnormality of thyroid hormones in patients with type A hepatic encephalopathy.A型肝性脑病患者甲状腺激素异常。
Oncotarget. 2017 Jun 29;8(40):67821-67828. doi: 10.18632/oncotarget.18869. eCollection 2017 Sep 15.
5
Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.经颈静脉肝内门体分流术(TIPS)后肝性脑病的发生率,根据其严重程度和时间分级分类。
Radiol Med. 2017 Sep;122(9):713-721. doi: 10.1007/s11547-017-0770-6. Epub 2017 May 16.
6
Is propofol safe when administered to cirrhotic patients during sedative endoscopy?丙泊酚用于肝硬化患者镇静内镜检查时是否安全?
Korean J Intern Med. 2014 Jan;29(1):57-65. doi: 10.3904/kjim.2014.29.1.57. Epub 2014 Jan 2.
7
Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.目前肝性脑病和非肝硬化性高氨血症性脑病的发病机制研究进展。
World J Gastroenterol. 2013 Jan 7;19(1):26-34. doi: 10.3748/wjg.v19.i1.26.
8
Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?乳果糖、利福昔明或支链氨基酸治疗肝性脑病:有何证据?
Metab Brain Dis. 2013 Jun;28(2):221-5. doi: 10.1007/s11011-012-9372-0. Epub 2012 Dec 29.
9
Organic delirious states and other psychiatric disorders: lessons for the hepatologists.有机性谵妄状态和其他精神障碍:对肝病学家的启示。
Metab Brain Dis. 2013 Jun;28(2):235-8. doi: 10.1007/s11011-012-9340-8. Epub 2012 Nov 6.